16 active not recruiting. 16 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Active not recruiting 16 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma Fp/ABS, FP, ABS - Asthma | Phase 3 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 649 | 2024-12-12 | 2026-10-06 |
| Oral Intake of Mg in Controlled Asthmatic Patients Magnesium, ICS+LABA - Bronchial Asthma | Phase 2 / Phase 3 | Active not recruiting | Zagazig University | 166 | 2024-11-02 | 2025-08-14 |
| Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) - Severe Asthma | Phase 3 | Active not recruiting | AstraZeneca | 310 | 2024-09-30 | 2026-10-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease INCA034176 - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Biosciences Japan GK | 21 | 2024-07-30 | 2026-10-05 |
| A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. Belumosudil, Placebo, Prednisone - Chronic Graft Versus Host Disease | Phase 3 | Active not recruiting | Sanofi | 260 | 2024-01-23 | 2026-10-16 |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations TEV-56248, Albuterol sulfate - Asthma | Phase 3 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 2772 | 2023-08-30 | 2026-10-14 |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Astegolimab - Chronic Obstructive Pulmonary Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 2000 | 2023-06-28 | 2026-08-14 |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma Benralizumab, Placebo - Asthma | Phase 3 | Active not recruiting | AstraZeneca | 94 | 2023-04-05 | 2026-10-28 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Active not recruiting | Areteia Therapeutics | 600 | 2023-01-30 | 2025-09-05 |
| Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma FF/UMEC/VI - Asthma | Phase 3 | Active not recruiting | Dr. Grace Parraga | 31 | 2022-08-08 | 2025-08-29 |
| Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery Vilanterol and Umeclidinium Bromide, Placebo - Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | Samsung Medical Center | 204 | 2021-04-01 | 2026-06-26 |
| Deflazacort Vs. Prednisolone in Acute-stage ABPA Deflazacort, Prednisolone - Allergic Bronchopulmonary Aspergillosis | Phase 2 / Phase 3 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 150 | 2020-01-15 | 2025-02-28 |
| The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants EpiCeram - Eczema, Asthma | Phase 3 | Active not recruiting | University of Melbourne | 760 | 2018-03-06 | 2023-05-10 |
| Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review. - Bronchiolitis Obliterans Syndrome (BOS) | Phase 3 | Active not recruiting | Washington University School of Medicine | 280 | 2015-01-01 | 2026-04-06 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 539 | 2013-09-09 | 2026-10-01 |
Asthma (9) · Bronchiolitis Obliterans Syndrome (5) · Pulmonary Disease, Chronic Obstructive (2) · Pulmonary Eosinophilia (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Carcinoma, Non-Small-Cell Lung (1) · Eczema (1) · Food Hypersensitivity (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Waldenstrom Macroglobulinemia (1)
Lung Diseases (16) · Respiratory Tract Diseases (16) · Bronchial Diseases (14) · Immune System Diseases (14) · Hypersensitivity (9) · Hypersensitivity, Immediate (9) · Respiratory Hypersensitivity (9) · Bronchiolitis (5) · Bronchiolitis Obliterans (5) · Bronchitis (5) · Graft vs Host Disease (5) · Organizing Pneumonia (5) · Chronic Disease (3) · Disease Attributes (3)
Albuterol (3) · Photopheresis (2) · Prednisolone (2) · axatilimab (2) · ibrutinib (2) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Calcineurin Inhibitors (1) · Cyclosporine (1) · EpiCeram (1) · Everolimus (1) · Fluticasone (1) · Imatinib Mesylate (1) · KD025 (1) · Magnesium (1)
AstraZeneca (2) · Teva Branded Pharmaceutical Products R&D LLC (2) · Areteia Therapeutics (1) · Dr. Grace Parraga (1) · Hoffmann-La Roche (1) · Incyte Biosciences Japan GK (1) · Incyte Corporation (1) · Janssen Research & Development, LLC (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Samsung Medical Center (1) · Sanofi (1) · University of Melbourne (1) · Washington University School of Medicine (1) · Zagazig University (1)
United States (9) · Argentina (8) · Canada (7) · Germany (7) · Italy (7) · Poland (7) · South Korea (7) · Spain (7) · United Kingdom (7) · Czechia (6) · France (6) · Israel (6) · Mexico (6) · Australia (5) · Belgium (5)
Adrian J Lowe, Doctorate (1) · George J. Despotis, M.D. (1) · Grace E Parraga, PhD (1) · Mona Bafadhel, MD (1)
PMID 30312482, PMID 30867201, PMID 39393433
2023 (2)